Compare, Analyse GSK Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs MYLAN (US) - Comparison Results

GSK PHARMA     Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

MYLAN (US)
   Change

Mylan is one of the worlds leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industrys broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GSK PHARMA   MYLAN
EQUITY SHARE DATA
    GSK PHARMA
Mar-19
MYLAN
Dec-18
GSK PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs3,5953,478-   
Low Rs1,2531,914-   
Sales per share (Unadj.) Rs184.71,600.4-  
Earnings per share (Unadj.) Rs26.343.5-  
Cash flow per share (Unadj.) Rs29.2343.1-  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs126.31,731.4-  
Shares outstanding (eoy) m169.40514.50-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x13.11.7 779.2%   
Avg P/E ratio x92.262.0 148.6%  
P/CF ratio (eoy) x83.17.9 1,057.8%  
Price / Book Value ratio x19.21.6 1,232.2%  
Dividend payout %76.10-   
Avg Mkt Cap Rs m410,6261,387,238 29.6%   
No. of employees `0005.035.0 14.2%   
Total wages/salary Rs m5,3720-   
Avg. sales/employee Rs Th6,306.723,526.5 26.8%   
Avg. wages/employee Rs Th1,083.10-   
Avg. net profit/employee Rs Th898.0638.8 140.6%   
INCOME DATA
Net Sales Rs m31,281823,426 3.8%  
Other income Rs m1,0230-   
Total revenues Rs m32,304823,426 3.9%   
Gross profit Rs m6,009213,072 2.8%  
Depreciation Rs m486154,178 0.3%   
Interest Rs m639,604 0.0%   
Profit before tax Rs m6,54019,290 33.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2870-   
Tax Rs m2,373-3,069 -77.3%   
Profit after tax Rs m4,45422,359 19.9%  
Gross profit margin %19.225.9 74.2%  
Effective tax rate %36.3-15.9 -228.1%   
Net profit margin %14.22.7 524.4%  
BALANCE SHEET DATA
Current assets Rs m20,061459,800 4.4%   
Current liabilities Rs m14,543335,245 4.3%   
Net working cap to sales %17.615.1 116.6%  
Current ratio x1.41.4 100.6%  
Inventory Days Days5784 67.9%  
Debtors Days Days1493 15.1%  
Net fixed assets Rs m14,343159,731 9.0%   
Share capital Rs m1,694438 386.4%   
"Free" reserves Rs m19,7040-   
Net worth Rs m21,398890,796 2.4%   
Long term debt Rs m2961,455 0.0%   
Total assets Rs m39,1132,389,462 1.6%  
Interest coverage x1,091.01.5 73,365.0%   
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x0.80.3 232.1%   
Return on assets %11.42.6 439.7%  
Return on equity %20.82.5 829.3%  
Return on capital %31.93.2 1,004.2%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-6,5570-   
CASH FLOW
From Operations Rs m3,994171,108 2.3%  
From Investments Rs m-1,433-88,444 1.6%  
From Financial Activity Rs m-3,584-79,712 4.5%  
Net Cashflow Rs m-1,0231,418 -72.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 73.07 Rs / USD

Compare GSK PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare GSK PHARMA With: STRIDES PHARMA SCIENCE  LUPIN  FDC  NOVARTIS  SUVEN LIFE SCIENCES  



Today's Market

Nifty is Weak but Smallcaps Can Outperform(Momentum Moves)

The market see-sawed during the week with both the bulls and bears swinging it out. But in the end, it was the bears who won. The Nifty ended the day, the week, and the month at 14,529.15.

Related Views On News

GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY21); Net Profit Down 84.8% (Quarterly Result Update)

Oct 30, 2020 | Updated on Oct 30, 2020

For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Intraday Trading for a Living (Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021 (Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla (Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More
-->

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

Access Now: Eight Steps to Your Eight Figure Fortune
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

GSK PHARMA SHARE PRICE


Feb 26, 2021 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GSK PHARMA

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

FEATURED VIDEOS

Nifty is Weak but Smallcaps Can Outperform

Gold 65,000 and Silver 84,000 in 2022

How Long Before a Big Stock Market Crash

I Believe the Investment of the Year Will Be...

More Featured Videos

MARKET STATS